Daiichi Sankyo’s Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

Read more on News-Medical-Net

_{»crosslinked«}

Be Sociable, Share!

• 

Tagged with: adolescents • aged • approval • Benicar • children • Daiichi • Hypertension • receives • Sankyo's • Treatment

Filed under: Hypertension Books

Like this post? Subscribe to my RSS feed and get loads more!